Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2019-06-19 6-K BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI View Document
2019-06-19 6-K LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA View Document
2019-06-19 6-K BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA View Document
2019-06-18 6-K LYNPARZA APPROVED IN THE EU FOR 1ST-LINE View Document
2019-06-17 6-K CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT View Document
2019-06-12 6-K PUBLICATION OF A PROSPECTUS View Document
2019-06-06 6-K CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY View Document
2019-06-03 6-K BLOCK LISTING INTERIM REVIEW View Document
2019-06-03 6-K TOTAL VOTING RIGHTS View Document
2019-06-03 6-K LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM View Document
2019-05-10 6-K POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III View Document
2019-05-08 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2019-05-08 6-K DIRECTOR DECLARATION View Document
2019-05-08 6-K TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY View Document
2019-05-07 6-K CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT View Document
2019-05-03 6-K QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES View Document
2019-05-01 6-K TOTAL VOTING RIGHTS View Document
2019-05-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2019-04-29 6-K LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST View Document
2019-04-26 6-K RESULT OF AGM View Document
2019-04-26 6-K AZN: Q1 2019 RESULTS View Document
2019-04-10 6-K LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE View Document
2019-04-04 6-K HOLDING(S) IN COMPANY View Document
2019-04-03 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2019-04-02 6-K TOTAL VOTING RIGHTS View Document
2019-04-01 6-K TOTAL VOTING RIGHTS View Document
2019-04-01 6-K SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION View Document
2019-03-29 6-K RESULTS OF PLACING View Document
2019-03-29 6-K AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL View Document
2019-03-27 6-K FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES View Document
2019-03-25 6-K FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES View Document
2019-03-18 6-K US FDA GRANTS SARACATINIB ODD FOR IPF View Document
2019-03-14 6-K NOTICE OF AGM View Document
2019-03-14 6-K 6-K View Document
2019-03-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2019-03-06 6-K FILING OF FORM 20-F WITH SEC View Document
2019-03-05 IRANNOTICE IRANNOTICE View Document
2019-03-05 20-F 20-F View Document
2019-03-05 6-K ANNUAL FINANCIAL REPORT View Document
2019-03-01 6-K TOTAL VOTING RIGHTS View Document
2019-03-01 6-K LYNPARZA RECEIVES POSITIVE EU CHMP OPINION View Document
2019-02-26 6-K LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION View Document
2019-02-25 6-K BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT View Document
2019-02-14 6-K ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS View Document
2019-02-12 SC 13G/A SEC SCHEDULE 13G View Document
2019-02-06 6-K US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION View Document
2019-02-05 6-K US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION View Document
2019-02-05 6-K EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 View Document
2019-02-04 SC 13G/A View Document
2019-02-01 6-K TOTAL VOTING RIGHTS View Document
2019-02-01 6-K FORXIGA RECEIVES POSITIVE EU CHMP OPINION View Document
2019-01-30 SC 13G SC 13G View Document
2019-01-25 6-K COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS View Document
2019-01-07 6-K ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES View Document
2019-01-02 6-K TOTAL VOTING RIGHTS View Document
2018-12-20 6-K BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD View Document
2018-12-20 6-K LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL View Document
2018-12-20 6-K PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS View Document
2018-12-19 6-K FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY View Document
2018-12-18 6-K ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE View Document
2018-12-14 6-K DIRECTORATE CHANGE View Document
2018-12-07 6-K UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI View Document
2018-12-06 6-K DIVESTMENT OF RIGHTS TO COVIS COMPLETED View Document
2018-12-04 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-12-03 6-K BLOCK LISTING INTERIM REVIEW View Document
2018-12-03 6-K TOTAL VOTING RIGHTS View Document
2018-12-03 6-K GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED View Document
2018-11-26 6-K US FDA GRANTS FASENRA ODD FOR EGPA View Document
2018-11-16 25-NSE View Document
2018-11-16 25-NSE View Document
2018-11-16 6-K ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC View Document
2018-11-13 6-K ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI View Document
2018-11-13 6-K US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA View Document
2018-11-13 6-K FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR View Document
2018-11-08 6-K AZN: YEAR-TO-DATE AND Q3 2018 RESULTS View Document
2018-11-06 6-K DIVESTMENT OF RIGHTS TO COVIS PHARMA View Document
2018-11-01 6-K TOTAL VOTING RIGHTS View Document
2018-10-31 6-K ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL View Document
2018-10-30 6-K GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVO View Document
2018-10-29 SC 13D SC 13D View Document
2018-10-24 4 FORM 4 SUBMISSION View Document
2018-10-23 6-K ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION View Document
2018-10-22 6-K LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER View Document
2018-10-19 6-K CHMP POSITIVE OPINION BEVESPI AEROSPHERE View Document
2018-10-17 3 FORM 3 SUBMISSION View Document
2018-10-16 6-K FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCER View Document
2018-10-12 SC 13D/A SC 13D/A View Document
2018-10-05 SC 13D SC 13D View Document
2018-10-02 4 FORM 4 SUBMISSION View Document
2018-10-01 6-K TOTAL VOTING RIGHTS View Document
2018-10-01 6-K ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED View Document
2018-09-28 6-K PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED View Document
2018-09-25 3 FORM 3 SUBMISSION View Document
2018-09-25 6-K OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLC View Document
2018-09-24 6-K EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC View Document
2018-09-24 6-K FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58 View Document
2018-09-14 6-K FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIA View Document
2018-09-07 6-K TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION View Document
2018-09-06 6-K DIRECTORATE CHANGE View Document
2018-09-04 6-K TOTAL VOTING RIGHTS View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas